Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Immunohistochemistry [2]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- V2116 - Provider product page
- Provider
- NSJ Bioreagents
- Product name
- MART-1 Antibody
- Antibody type
- Monoclonal
- Antigen
- Recombinant human MART-1 protein was used as the immunogen for this antibody.
- Description
- Protein G purified antibody
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antibody clone number
- M2-7C10
- Vial size
- 20 µg, 100 µg (with sodium azide), 100 µg (without sodium azide), 7 ml (prediluted for IHC use, if applicable)
- Storage
- Store the MART-1 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
Submitted references Epithelioid malignant peripheral nerve sheath tumor: clinicopathologic analysis of 63 cases.
Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy.
Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration.
Melan-A, a new melanocytic differentiation marker.
Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors.
Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
Jo VY, Fletcher CD
The American journal of surgical pathology 2015 May;39(5):673-82
The American journal of surgical pathology 2015 May;39(5):673-82
Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy.
Uppada SB, Erickson T, Wojdyla L, Moravec DN, Song Z, Cheng J, Puri N
International journal of nanomedicine 2014;9:43-53
International journal of nanomedicine 2014;9:43-53
Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration.
Bartlett EK, Fetsch PA, Filie AC, Abati A, Steinberg SM, Wunderlich JR, White DE, Stephens DJ, Marincola FM, Rosenberg SA, Kammula US
Clinical cancer research : an official journal of the American Association for Cancer Research 2014 May 15;20(10):2607-16
Clinical cancer research : an official journal of the American Association for Cancer Research 2014 May 15;20(10):2607-16
Melan-A, a new melanocytic differentiation marker.
Busam KJ, Jungbluth AA
Advances in anatomic pathology 1999 Jan;6(1):12-8
Advances in anatomic pathology 1999 Jan;6(1):12-8
Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors.
Busam KJ, Iversen K, Coplan KA, Old LJ, Stockert E, Chen YT, McGregor D, Jungbluth A
The American journal of surgical pathology 1998 Jan;22(1):57-63
The American journal of surgical pathology 1998 Jan;22(1):57-63
Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996 May;19(3):192-205
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996 May;19(3):192-205
No comments: Submit comment
Supportive validation
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- IHC testing of human melanoma stained with MART-1 antibody (M2-7C10). Note cytoplasmic staining of cells.
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- IHC testing of human melanoma stained with MART-1 antibody (M2-7C10). Note cytoplasmic staining of cells.
Supportive validation
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- SDS-PAGE Analysis of Purified, BSA-Free MART-1 Antibody (clone M2-7C10). Confirmation of Integrity and Purity of the Antibody.
